Literature DB >> 15925365

An active transport system in the blood-brain barrier may reduce levodopa availability.

Richard A Hawkins1, Ashwini Mokashi, Ian A Simpson.   

Abstract

Levodopa, the primary drug used to treat patients with Parkinson's disease, is transported into the brain by the facilitative amino acid transporter (L1). We present here an unanticipated discovery: levodopa may be pumped out of the brain by a Na(+)-dependent transport system that couples the naturally occurring Na(+) gradient existing between the brain's extracellular fluid and the cytoplasm of capillary endothelial cells. The activity of this system reduces the net availability of levodopa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925365     DOI: 10.1016/j.expneurol.2005.04.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

Review 1.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

2.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

3.  Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells.

Authors:  Xiaobin Zhang; Daria Y Alakhova; Elena V Batrakova; Shu Li; Zhihui Yang; Yili Li; Alexander V Kabanov
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-02       Impact factor: 4.147

4.  Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease.

Authors:  Valerio Pisani; Alessandro Stefani; Mariangela Pierantozzi; Silvia Natoli; Paolo Stanzione; Diego Franciotta; Antonio Pisani
Journal:  J Neuroinflammation       Date:  2012-08-08       Impact factor: 8.322

5.  Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.

Authors:  Elva Fridjonsdottir; Reza Shariatgorji; Anna Nilsson; Theodosia Vallianatou; Luke R Odell; Luke S Schembri; Per Svenningsson; Pierre-Olivier Fernagut; Alan R Crossman; Erwan Bezard; Per E Andrén
Journal:  Sci Adv       Date:  2021-01-06       Impact factor: 14.136

6.  Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson's Disease.

Authors:  Lu Fang; Hangxu Ren; Xiyu Mao; Shanshan Zhang; Yu Cai; Shiyi Xu; Yi Zhang; Lihua Li; Xuesong Ye; Bo Liang
Journal:  Biosensors (Basel)       Date:  2022-02-07

7.  Why is there motor deterioration in Parkinson's disease during systemic infections-a hypothetical view.

Authors:  Florian Brugger; Roberto Erro; Bettina Balint; Georg Kägi; Paolo Barone; Kailash P Bhatia
Journal:  NPJ Parkinsons Dis       Date:  2015-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.